In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Commercial Strategies

Set Alert for Commercial Strategies

The Truly Transformational Potential Of AI Relies On The Data

Executives from several AI-focused biotechs emphasize that generating a truly innovative medicine, as opposed to a me-too drug, depends not just on the quantity, but on the quality of data used by the algorithm.

Commercial Strategies Artificial Intelligence

‘Why Am I Not Seeing More Women In The Hiring Mix?’ MedExec Women Founder Says It’s Time For Change

Maria Shepherd, co-founder of MedExec Women, a nonprofit that seeks to empower executive leaders in medtech, is preparing to host the group’s fifth annual conference in Boston, which is expected to draw 200 attendees. Shepherd spent more than two decades in the medical device industry before starting consulting firm Medi-Vantage. She talks to Medtech Insight about her own career path, how the industry is changing, and the importance of “grooming” the next generation of young medtech leaders.

Women's Health Commercial Strategies

Alys Is An Asset Play Wanting Big Pharma Attention

Leaders of a new dermatology-focused biotech, which has launched with 14 development programs in its pipeline, explain the rationale behind the company creation and the ideal exit scenario.

C-Suite Speaks Commercial Strategies

Unraveling #JPM24: Insights From Citeline Reporters And Analysts

As it often does, this year's J.P. Morgan Healthcare Conference could set the tone for the rest of the year in biopharma. In Vivo revisits the key questions coming out of the 2024 event. 

Market Intelligence Deals

Digital Health Roundup: CES Biggest Hits; Apple Versus Masimo; Insulet Recalls Diabetes App

In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights interviews with industry leaders in medtech and healthtech and demos of some of the most innovative tech seen at CES 2024 in Las Vegas. Hannah Daniel dives into the latest developments in the intellectual property dispute between Apple and Masimo over blood oxygen sensors in the newer Apple Watch models.

Digital Health Artificial Intelligence

Effective Integration Is The Key To BD Success For Ipsen

At the 2023 BIO-Europe conference, In Vivo sat down with Ipsen’s EVP and chief business officer, Philippe Lopes-Fernandes, to discuss the company’s business development strategy and future goals.

C-Suite Speaks Commercial Strategies

Outlook 2024: Shaping A Medtech Environment Where Technology Leads The Way

Environmental demands, the evolution of care models, new delivery technologies and AI tools are influencing how medtechs must approach innovation.

Commercial Strategies Outlook 2024

Industry Leaderboard Gains And Dips Were Still Marked By COVID-19

Pfizer held the number one spot on the Scrip 100 on the strength of its COVID-19 products, while some others faced challenging financial comparisons in 2022 because of COVID-19 headwinds.

Outlook 2024 Commercial Strategies

Big Pharma Shouts, Generics And Biosimilars Whisper: M&A In 2023

“A lot of companies are hurting because of the higher interest rates,” one major CEO observed recently, summing up a year which saw little headline-grabbing news on the M&A front for generic and biosimilar sponsors.

C-Suite Speaks Commercial Strategies

Europe’s Biotech Sector Still In Reasonable Shape

Money may have become too tight to mention for many biotechs and the IPO window in Europe is not just shut but boarded up. However, big pharma’s need to replenish the pipeline has become urgent and the major players are looking to tap into the continent’s early-stage companies which are driving innovation and provide them with much-needed cash.

Financing C-Suite Speaks

Industry CEOs Talk Drug Pricing, Value And The IRA

Value-based pricing for drugs remains largely a pipe dream in the US, industry leaders say, even as drug pricing pressure mounts. 

C-Suite Speaks Commercial Strategies

Global Pharma Companies Must Nurture ‘Intercultural Intelligence’

Equality, Diversity and Inclusion (ED&I) carries huge potential for business and society. However, various events around the globe, including the Black Lives Matter movement, highlighted that there are unaddressed challenges which need to be tackled. PTC Therapeutics, a global biopharmaceutical company with presence in in Europe, Middle East and Africa (EMEA) has initiated a new ED&I program to further strengthen its values and encourage positive progress globally. 

Diversity & Inclusion C-Suite Speaks

‘Build A Company To Be Bought, Not Sold,' 'Match The Asset To The Capital,' And Other Advice From VC Experts

At the recent LSX World Congress USA in Boston, Medtech Insight’s Reed Miller moderated a panel of experienced medtech investors to discuss the current medtech venture financing environment and offer advice for entrepreneurs raising money to support their innovations.

Commercial Strategies Commercial

A Next-Gen Approach To Health Care Risk And Compliance

Across the health care industry, the increasing numbers of ethics violations, data breaches and reputational challenges reflect the growing magnitude and prevalence of compliance failures.

Commercial Strategies Business Strategies

Spinning Around – One Company's Bid To Diagnostic-ify The Metabolism

Lifespin is working on tools to characterize a patient’s metabolism and provide more detailed information about a disease.

In Vitro Diagnostics Metabolic

Abbott Buys Bigfoot Biomedical – But What Lurks In The Forest?

Abbott and Bigfoot Biomedical have worked as partners for more than half a decade but will now continue as one. Analysts are questioning whether the merger will simply be a tuck-in for Abbott, or enable it to release an insulin pump of their own.

M & A Diabetic Care
See All
UsernamePublicRestriction

Register